Acumen Pharmaceuticals To Present Clinical Trial Design For INTERCEPT-AD Phase 1 Placebo-Controlled, Single-And Multiple-Dose Clinical Trial Of ACU193, At 2021 Clinical Trials On Alzheimer's Disease (CTAD) Conference Nov. 9-12